The CHRU Community Advisory Board


Clinical trial participants make scientific research possible and advance science

Participants around the Clinical HIV Research Unit (CHRU) clinical research sites in Johannesburg, Durban and Port Elizabeth play a major role in working with our scientists to test new medicines and find better and easier ways to treat diseases like HIV, TB and HIV-associated cancers. In early 2020, Covid-19 vaccine trials began, kicking off with the Janssen Covid-19 vaccine study.

CHRU is involved in breakthrough research. Our scientists are highly regarded internationally. Without participants like you, our work and medical breakthroughs would not be possible.

Clinical trial participants, who are protected by rigorous South African and international regulations, as well as by our community advisory boards, help us advance science, change treatment guidelines and improve public health outcomes that benefit society.

Participants have played a vital part in numerous breakthrough studies. These include:

  • The ENSEMBLE study which tested the Johnson & Johnson Covid-19 vaccine to find a safe vaccine for South Africans and people across the world.
  • The Study Strategic Timing of Antiretroviral Treatment (START) study which showed that HIV-infected people have a lower risk of developing AIDS with the early introduction of antiretroviral treatment (ART).
  • The HPTN 052 study which determined that early introduction of ART for someone with HIV whose partner does not have HIV helps prevent HIV transmission.
  • The STREAM study which evaluated a new regimen and slashed treatment duration for multi-drug resistant (MDR) TB.
  • The NIH’s ACTG A5279 study whichshowed that a one-month, ultra-short TB preventive course could be important in the global control of HIV-associated TB.
  • The Nix-TB TB Alliance trial, the results of which were presented to the US Government’s Food and Drug Administration Advisory Committee in June 2019.
  • The Bedaquiline Clinical Access Program which led to the SA National Department of Health’s introduction of Bedaquiline as the standard care for MDR-TB in 2018.
  • The nurse-initiated management of antiretroviral treatment (NIMART) study revealed that professional nurses can initiateantiretroviral treatment, alleviating the pressure on doctors in facilities.

Consider participating in our upcoming studies.

Watch what it’s like being a clinical trial participant: Nkululeko Masuku, CHRU clinical trial participant, ends his battle with TB

Participate in a clinical trial

At the Clinical HIV Research Unit (CHRU), we run studies to treat and prevent HIV, Tuberculosis (TB) including drug-resistant TB, HIV-associated cancers including cervical cancer, and Covid-19. Our participants receive attentive care from international scientists and doctors based on the study protocol and make a contribution to society. All our studies comply with the highest ethical standards and regulations.

If you would like to know more, or take part in a study, sign up here.